Nipro Corporation (JP:8086)
:8086
Want to see JP:8086 full AI Analyst Report?
Top Page
Nipro
(8086)
Select Model
Select Model
Rating:54Neutral
Price Target:
¥1,663.00
▲(10.68% Upside)
Action:Reiterated
Date:05/14/26
The score is primarily held back by financial risk—high leverage and consistently negative free cash flow—despite steady revenue growth. Technicals are mixed (price above moving averages but weak momentum), while valuation is moderate with a modest dividend yield.
Positive Factors
Recurring consumables revenue
Nipro’s product mix includes single-use clinical supplies and dialysis consumables that are consumed per treatment. This creates durable, repeatable revenue streams tied to chronic therapies and installed equipment, improving revenue visibility and resilience over multiple years.
Negative Factors
High leverage
Elevated debt levels materially constrain financial flexibility and raise refinancing and interest-rate risk. Even with improvement from prior years, leverage at ~2.3x equity limits the company’s ability to absorb shocks, pursue opportunistic investments, or accelerate deleveraging without reducing operating investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
Nipro’s product mix includes single-use clinical supplies and dialysis consumables that are consumed per treatment. This creates durable, repeatable revenue streams tied to chronic therapies and installed equipment, improving revenue visibility and resilience over multiple years.
Read all positive factors
Nipro (8086) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥278.49B
Dividend Yield2.03%
Average Volume (3M)504.50K
Price to Earnings (P/E)20.8
Beta (1Y)0.41
Revenue Growth2.47%
EPS Growth164.11%
CountryJP
Employees38,117
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)66.77
Shares Outstanding171,459,470
10 Day Avg. Volume391,050
30 Day Avg. Volume504,500
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.92
Price to Sales (P/S)0.38
P/FCF Ratio-32.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,500.00Price Target Upside-0.17% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)79.07
Revenue Forecast (FY)¥697.91B
Nipro Business Overview & Revenue Model
Company Description
Nipro Corporation (8086) is a global healthcare company headquartered in Japan, specializing in the development and manufacturing of medical devices, pharmaceuticals, and biotechnology. The company operates primarily in the areas of renal care, in...
How the Company Makes Money
Nipro makes money primarily by selling medical devices and consumables used in routine clinical care and chronic therapies, along with pharmaceutical packaging and drug-delivery related components supplied to drug manufacturers. Key revenue stream...
Nipro Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
44
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 649.95B | 660.54B | 644.59B | 586.78B | 545.20B | 494.79B |
| Gross Profit | 196.66B | 208.28B | 193.66B | 173.98B | 165.90B | 151.84B |
| EBITDA | 93.57B | 101.36B | 92.25B | 81.21B | 66.47B | 70.05B |
| Net Income | 10.89B | 13.50B | 5.11B | 11.11B | 4.58B | 13.46B |
Balance Sheet | ||||||
| Total Assets | 1.15T | 1.21T | 1.18T | 1.12T | 1.04T | 938.35B |
| Cash, Cash Equivalents and Short-Term Investments | 109.97B | 97.83B | 106.67B | 99.67B | 89.68B | 95.34B |
| Total Debt | 642.04B | 638.31B | 636.87B | 635.69B | 605.93B | 564.85B |
| Total Liabilities | 855.88B | 878.51B | 864.77B | 849.18B | 793.62B | 738.49B |
| Stockholders Equity | 238.94B | 274.12B | 252.45B | 232.66B | 206.32B | 185.24B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -7.67B | -8.15B | -21.33B | -74.70B | -11.74B |
| Operating Cash Flow | 0.00 | 54.66B | 68.46B | 72.94B | 10.39B | 68.21B |
| Investing Cash Flow | 0.00 | -55.33B | -71.88B | -87.08B | -71.74B | -78.43B |
| Financing Cash Flow | 0.00 | -8.14B | 5.38B | 22.14B | 43.08B | 10.30B |
Nipro Technical Analysis
Positive
1502.50
Price Trends
1589.36
Positive
1533.23
Positive
1502.99
Positive
Market Momentum
43.31
Negative
66.11
Neutral
82.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8086, the sentiment is Positive. The current price of 1502.5 is below the 20-day moving average (MA) of 1615.60, below the 50-day MA of 1589.36, and below the 200-day MA of 1502.99, indicating a bullish trend. The MACD of 43.31 indicates Negative momentum. The RSI at 66.11 is Neutral, neither overbought nor oversold. The STOCH value of 82.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8086.
Nipro Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥975.60B | 32.62 | 11.64% | 0.82% | 15.13% | 196.11% | |
71 Outperform | ¥3.55T | 26.06 | 8.98% | 1.22% | 9.24% | 16.68% | |
65 Neutral | ¥2.01T | 28.96 | 11.34% | 1.01% | 1.34% | -40.50% | |
57 Neutral | ¥861.51B | 24.42 | 9.38% | 1.88% | -1.70% | -33.90% | |
54 Neutral | ¥278.49B | 20.79 | 4.38% | 2.03% | 2.47% | 164.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:8086
Nipro
1,721.00
488.28
39.61%
JP:4543
Terumo
2,401.00
-189.55
-7.32%
JP:7747
Asahi Intecc Co
3,766.00
1,555.76
70.39%
JP:7733
Olympus
1,785.50
-18.42
-1.02%
JP:6869
Sysmex
1,397.00
-944.84
-40.35%
Nipro Corporate Events
Nipro Raises Year-End Dividend, Lifts Annual Payout to 29 Yen Per Share
May 12, 2026
Nipro’s board has approved a year-end dividend of 19 yen per share for the fiscal year ended March 31, 2026, up from 13 yen a year earlier and exceeding its February forecast of 18 yen. The total payout will be 3.11 billion yen, with the com...
Nipro books FX loss but gains subsidy for new antibiotic plant
May 12, 2026
Nipro Corporation reported that it booked ¥4.19 billion in foreign exchange losses as non-operating expenses for the fiscal year ended March 31, 2026, reflecting currency fluctuations over the period. At the same time, a subsidiary’s pr...
Nipro lifts profits and dividend as earnings, balance sheet strengthen
May 12, 2026
Nipro reported fiscal-year 2026 consolidated net sales of ¥660.5 billion, up 2.5%, with operating profit surging 41.5% to ¥37.6 billion and profit attributable to owners of the parent jumping 164.1% to ¥13.5 billion, driven by margi...
Nipro to Shift Domestic Depreciation Method to Align With Overseas Operations
Mar 24, 2026
Nipro announced that it will change the depreciation method for property, plant, and equipment at the parent company and domestic consolidated subsidiaries from the declining-balance method to the straight-line method. The shift reflects that over...
Nipro Sets Record Date and Confirms Higher Year-End Dividend Forecast
Mar 11, 2026
Nipro Corporation’s board has set March 31, 2026 as the record date for shareholders eligible to receive the year-end dividend for the fiscal year ending March 2026, with notice to be provided electronically via its website. The company reaf...
Nipro Expands Governance With New Nomination and Compensation Committee
Feb 25, 2026
Nipro Corporation has decided to upgrade its existing Compensation Committee into a broader Nomination and Compensation Committee as a voluntary advisory body to the Board of Directors. The move, effective April 1, 2026, is designed to enhance fai...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.